In searching for an optimal induction regimen , we conducted two separate randomized trials of @ living donor and @ deceased donor adult , primary kidney transplant recipients comparing antithymocyte globulin ( Thymoglobulin ) ( group A , N = @ ) versus alemtuzumab ( group B , N = @ ) versus daclizumab ( group C , N = @ ) , using exactly the same three treatment arms in each trial .